Levi & Korsinsky notifies investors that it has commenced an investigation into Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) concerning potential violations of the federal securities laws.
Ionis Pharmaceuticals shares were falling more than 20% on July 9, 2026, after the Company disclosed that its Phase-3 CARDIO-TTRansform trial failed to meet its primary endpoint. The investigation concerns whether the Company's prior public statements regarding the CARDIO-TTRansform program aligned with the trial's ultimate outcome. On November 6, 2024, CEO Brett Monia stated on the Company's Q3 2024 earnings call that the "ongoing CARDIO-TTRansform trial [was] on track to deliver the most comprehensive dataset in these patients in the second half of 2026." More recently, on June 10, 2026, CEO Monia reiterating that data was expected in the back half of the year, told investors “everything is going very well in the conduct of the study and the execution. The study is reasonably derisked for its primary endpoint. We’re excited.” On July 9, 2026, the company disclosed that its trial, partnered with AstraZeneca, did not meet its primary endpoint of reducing combined cardiovascular death and recurrent events in transthyretin-mediated amyloid cardiomyopathy patients. The stock opened down more than 20% on the news.
If you suffered a loss on your Ionis Pharmaceuticals, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





